Large-scale human genetics to identify novel drug targets

Dr. Shuldiner's major research interests lie in the molecular biology and genetics age-related diseases including of diabetes, obesity, osteoporosis, and cardiovascular disease, common disorders that contribute significantly to mortality, morbidity, and functional loss. He also works on the pharmaco- and nutri-genomics of these disorders. He is best known for his research in the Old Order Amish, a homogeneous founder population ideal for genetic studies. His multidisciplinary research team made several important genetic discoveries that have informed human biology and therapeutics including the first human null mutations in genes encoding apolipoprotein C-III (APOC3) and hormone sensitive lipase (LIPE), as well as discovery that common loss of function variants in CYP2C19 are major determinants of response to clopidogrel (Plavix) in coronary heart disease patients. In September 2014, Dr. Shuldiner became Vice President of the Regeneron Genetics Center where he continues to work in discovery and translational genomics, applying high-throughput sequencing and analytical approaches with academic collaborators throughout the world.

Dr. Shuldiner has authored more than 350 original articles in leading journals and 70 reviews and book chapters. He is the recipient of a number of awards including the prestigious Paul Beeson Physician Faculty Scholar award, Ellison Medical Foundation Senior Scholar award, and 2006 University of Maryland Founders Day Researcher of the Year award.